Enzalutamide preferable to bicalutamide plus LHRH analogue in prostate cancer

Developments in clinical trials and health information technology that will improve targeted therapies for patients

Effective adjuvant chemotherapy for high-risk, localised prostate cancer

First effective adjuvant chemotherapy for high-risk, localised prostate cancer

Genomic marker predicts anti-PD-1 response in several cancers

ecancermedicalscience editor's choice for May 2015

Prostate cancer and pharmacokinetics: Expert discussion

Developing technical improvements to bladder radiotherapy using online imaging

Advances in prostate cancer focal radiation treatments

Comparison of coplanar and non-coplanar beam plans as treatment for prostate SBRT

Developments of tumour control probability (TCP) models for prostate cancer patients

Certain classes of genes in patients that could lead to prostate cancer